Jennifer Ho

Vice President of Research and Clinical Development
Shine-On BioMedical
 

​

Dr. Jennifer Ho is currently VP of Res&Clin Development at ShineOn BioMedical leading first-in-class drug development on nanobody-based tri-specific antibody and HLA-G targeted exosome for solid tumor treatment. Dr. Ho a physician-scientist and pharmaceutical executive with 15-year extensive expertise in scientific and clinical research, supervise non-clinical, CMC, clinical development and operation. With over a decade of leadership experience in the biopharmaceutical industry, she has played a pivotal role in developing first-in-class stem cell therapies targeting neurodegenerative diseases, multi-specific antibodies as well as engineered exosomal drugs targeting solid tumors, and inhaled biological drug for respiratory infections.
Prior to Year 2023, she held 8-year SVP of Clinical Dev and Operation at Ansun Biopharma and Steminent Biotherapeutics at San Diego, CA, USA, where she led global clinical trials, regulatory operations, and drug development programs across the U.S., Asia-Pacific, and Europe.
Dr. Ho's career spans academia and clinical practice. Her groundbreaking work has earned her numerous awards, including the prestigious Wu Ta-You Research Award in 2015. She holds an MD from National Taiwan University, a PhD in Biopharmaceutical Science from National Yang-Ming University, and a law degree from National Taipei University. She is currently a Professor of Ophthalmology at China Medical University Hospital. She previously served as a professor at National Yang-Ming University, Taipei Medical University and a visiting professor at UC San Diego contributed to over 60 peer-reviewed publications.​
​

Speech title & Synopsis

Asia Biotech view on decision making on outsourcing in the current changing economic environment​

.